Health Care & Life Sciences » Biotechnology | Asterias Biotherapeutics Inc.

Asterias Biotherapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
49,791.60
17,450.10
28,189.00
35,069.00
21,595.00
Total Accounts Receivable
-
495.90
567.00
-
-
Other Current Assets
340.10
438.30
1,033.00
1,921.00
1,121.00
Total Current Assets
50,131.70
18,384.20
29,789.00
36,990.00
22,716.00
Net Property, Plant & Equipment
1,460.50
1,450.60
5,756.00
5,475.00
4,543.00
Total Investments and Advances
415.50
415.50
416.00
-
-
Intangible Assets
28,291.60
23,502.20
20,816.00
18,130.00
15,444.00
Other Assets
54.40
361.00
457.00
415.00
389.00
Total Assets
83,332.10
44,113.50
57,234.00
61,010.00
43,092.00
ST Debt & Current Portion LT Debt
-
-
7.00
7.00
7.00
Accounts Payable
567.10
736.90
747.00
1,076.00
401.00
Income Tax Payable
-
4,712.90
-
-
-
Other Current Liabilities
17,728.60
1,046.50
4,226.00
4,968.00
3,113.00
Total Current Liabilities
18,295.80
6,496.30
4,980.00
6,051.00
3,521.00
Long-Term Debt
-
-
26.00
20.00
14.00
Deferred Taxes
8,277.50
4,514.40
2,550.00
-
-
Other Liabilities
-
471.70
4,579.00
12,911.00
6,014.00
Total Liabilities
29,551.60
11,482.50
12,135.00
18,982.00
9,549.00
Common Equity (Total)
53,780.50
32,631.10
45,099.00
42,028.00
33,543.00
Total Shareholders' Equity
53,780.50
32,631.10
45,099.00
42,028.00
33,543.00
Total Equity
53,780.50
32,631.10
45,099.00
42,028.00
33,543.00
Liabilities & Shareholders' Equity
83,332.10
44,113.50
57,234.00
61,010.00
43,092.00

About Asterias Biotherapeutics

View Profile
Address
6300 Dumbarton Circle
Fremont California 94555
United States
Employees -
Website http://www.asteriasbiotherapeutics.com
Updated 09/14/2018
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.